Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Sexually Transmitted Diseases

Free Subscription Articles published in Oral Oncol Retrieve available abstracts of 101 articles: HTML format

Single Articles

July 2024
1. DAUNGSUPAWONG H, Wiwanitkit V
   Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
   Oral Oncol. 2024;156:106930.
   PubMed    
   
   
   
2. CHEN AM
   Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
   Oral Oncol. 2024;154:106850.
   PubMed     Abstract available
   
   
   June 2024
3. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
   Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
   Oral Oncol. 2024;156:106894.
   PubMed     Abstract available
   
   
   
4. HARIDEVAMUTHU B
   Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
   Oral Oncol. 2024;155:106895.
   PubMed    
   
   
   
5. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
   Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
   Oral Oncol. 2024;155:106874.
   PubMed     Abstract available
   
   
   
6. BABU S, Krishnan M
   Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
   Oral Oncol. 2024;153:106824.
   PubMed    
   
   
   May 2024
7. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
   Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
   Oral Oncol. 2024;154:106855.
   PubMed     Abstract available
   
   
   April 2024
8. WATON A, Chambers A, Fox H, O'Hara J, et al
   Human Papilloma Virus-16 associated primary adenocarcinoma of the tonsil: Report of two cases and literature review.
   Oral Oncol. 2024;151:106766.
   PubMed    
   
   
   March 2024
9. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
   Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
   Oral Oncol. 2024;151:106749.
   PubMed     Abstract available
   
   
   
10. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available
    
    
    
11. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available
    
    
    February 2024
12. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available
    
    
    
13. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    PubMed     Abstract available
    
    
    January 2024
14. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    PubMed     Abstract available
    
    
    December 2023
15. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    PubMed     Abstract available
    
    
    November 2023
16. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    PubMed     Abstract available
    
    
    
17. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    PubMed     Abstract available
    
    
    October 2023
18. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    PubMed     Abstract available
    
    
    September 2023
19. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    PubMed     Abstract available
    
    
    
20. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    PubMed     Abstract available
    
    
    
21. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    PubMed    
    
    
    August 2023
22. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    PubMed     Abstract available
    
    
    
23. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    PubMed     Abstract available
    
    
    July 2023
24. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    PubMed     Abstract available
    
    
    
25. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    PubMed     Abstract available
    
    
    
26. DAHLSTROM KR, Sikora AG, Liu Y, Chang CC, et al
    Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
    Oral Oncol. 2023;142:106401.
    PubMed     Abstract available
    
    
    May 2023
27. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    PubMed    
    
    
    April 2023
28. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    PubMed     Abstract available
    
    
    March 2023
29. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    PubMed     Abstract available
    
    
    
30. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    PubMed     Abstract available
    
    
    
31. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    PubMed    
    
    
    
32. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    PubMed     Abstract available
    
    
    February 2023
33. BALLAL Y, Gete M, Su J, O'Sullivan B, et al
    The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.
    Oral Oncol. 2023;138:106332.
    PubMed     Abstract available
    
    
    
34. BOOT PA, Mes SW, de Bloeme CM, Martens RM, et al
    Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;137:106307.
    PubMed     Abstract available
    
    
    January 2023
35. HALLER TJ, Yin XL, O'Byrne TJ, Moore EJ, et al
    30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: A retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675).
    Oral Oncol. 2023;137:106248.
    PubMed     Abstract available
    
    
    December 2022
36. IDA S, Takahashi H, Tada H, Mito I, et al
    Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;137:106296.
    PubMed     Abstract available
    
    
    
37. PERES MA, Huihua L, Antunes JLF, Perea LME, et al
    Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017.
    Oral Oncol. 2022;136:106272.
    PubMed     Abstract available
    
    
    
38. TAPIA M, Manji J, Dhillon K, Kleid S, et al
    The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
    Oral Oncol. 2022;135:106213.
    PubMed     Abstract available
    
    
    November 2022
39. GHEIT T, Muwonge R, Lucas E, Galati L, et al
    Impact of HPV vaccination on HPV-related oral infections.
    Oral Oncol. 2022;136:106244.
    PubMed     Abstract available
    
    
    
40. CHAN JYK, Cheung MK, Lan L, Ng C, et al
    Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
    Oral Oncol. 2022;135:106245.
    PubMed     Abstract available
    
    
    October 2022
41. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Corrigendum to "Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma" [Oral Oncol. 134 (2022) 106131].
    Oral Oncol. 2022 Oct 20:106212. doi: 10.1016/j.oraloncology.2022.106212.
    PubMed    
    
    
    
42. MANJUSHA M, Yasasve M, Manojj D, Saravanan M, et al
    Role of human papilloma virus in the cross-talk mechanism between NF-kappaB and specific AP-1 proteins during tongue carcinogenesis.
    Oral Oncol. 2022;133:106062.
    PubMed    
    
    
    September 2022
43. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;134:106131.
    PubMed     Abstract available
    
    
    August 2022
44. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    
    
    
    June 2022
45. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available
    
    
    May 2022
46. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available
    
    
    
47. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    
    
    
    
48. BURMAN B, Drutman SB, Fury MG, Wong RJ, et al
    Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
    Oral Oncol. 2022;128:105806.
    PubMed     Abstract available
    
    
    April 2022
49. SARODE SC, Sarode GS, Sengupta N
    Strengthening koilocyte as a biomarker of HPV infection: A need of the hour.
    Oral Oncol. 2022;129:105891.
    PubMed    
    
    
    
50. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available
    
    
    
51. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available
    
    
    March 2022
52. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available
    
    
    
53. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available
    
    
    February 2022
54. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available
    
    
    
55. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available
    
    
    
56. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available
    
    
    January 2022
57. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available
    
    
    
58. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    
    
    
    December 2021
59. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available
    
    
    
60. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    
    
    
    November 2021
61. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available
    
    
    
62. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available
    
    
    
63. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available
    
    
    October 2021
64. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available
    
    
    
65. SHISHODIA G, Toledo RRG, Rong X, Zimmerman E, et al
    4NQO enhances differential activation of DNA repair proteins in HPV positive and HPV negative HNSCC cells.
    Oral Oncol. 2021;122:105578.
    PubMed     Abstract available
    
    
    
66. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available
    
    
    
67. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    
    
    
    September 2021
68. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available
    
    
    August 2021
69. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available
    
    
    
70. FIACCHINI G, Benettini G, Trico D, Torregrossa L, et al
    Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis.
    Oral Oncol. 2021;119:105252.
    PubMed     Abstract available
    
    
    July 2021
71. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available
    
    
    
72. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available
    
    
    
73. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available
    
    
    June 2021
74. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    PubMed     Abstract available
    
    
    
75. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available
    
    
    
76. BIDINOTTO AB, Kops NL, Bessel M, Maranhao AGK, et al
    Prevalence of oral HPV infection in unvaccinated young adults in Brazil.
    Oral Oncol. 2021;120:105396.
    PubMed     Abstract available
    
    
    
77. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    PubMed     Abstract available
    
    
    May 2021
78. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    
    
    
    
79. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    
    
    
    April 2021
80. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available
    
    
    
81. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available
    
    
    
82. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available
    
    
    
83. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    
    
    
    March 2021
84. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    PubMed     Abstract available
    
    
    February 2021
85. FREIHAT O, Toth Z, Pinter T, Kedves A, et al
    Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC).
    Oral Oncol. 2021;116:105239.
    PubMed     Abstract available
    
    
    
86. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    
    
    
    
87. CHATFIELD-REED K, Roche VP, Pan Q
    cfDNA detection for HPV+ squamous cell carcinomas.
    Oral Oncol. 2021;115:104958.
    PubMed     Abstract available
    
    
    
88. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    PubMed     Abstract available
    
    
    January 2021
89. YILMAZ E, Ozbun MA, Gan GN
    Molecular and immune signature of HPV-positive oral cavity squamous cell carcinoma.
    Oral Oncol. 2021 Jan 25:105175. doi: 10.1016/j.oraloncology.2020.105175.
    PubMed    
    
    
    
90. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available
    
    
    
91. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    
    
    
    December 2020
92. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available
    
    
    October 2020
93. FLEMING CW, Ward MC, Woody NM, Joshi NP, et al
    Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Oral Oncol. 2020;112:105046.
    PubMed     Abstract available
    
    
    
94. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2020;112:105041.
    PubMed     Abstract available
    
    
    
95. CONTRERA KJ, Smile TD, Mahomva C, Wei W, et al
    Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
    Oral Oncol. 2020;111:105030.
    PubMed     Abstract available
    
    
    June 2020
96. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    PubMed    
    
    
    April 2020
97. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    PubMed     Abstract available
    
    
    
98. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    PubMed     Abstract available
    
    
    March 2020
99. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    PubMed    
    
    
    January 2020
100. CHATFIELD-REED K, Gui S, O'Neill WQ, Teknos TN, et al
     HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.
     Oral Oncol. 2020;100:104488.
     PubMed     Abstract available
     
     
     
101. CHEN C, Lohavanichbutr P, Zhang Y, Houck JR, et al
     Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples.
     Oral Oncol. 2020;100:104487.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.